EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study

Jason J Luke iD, Paolo A Ascierto iD, Muhammad A Khattak, Luis de la Cruz Merino iD, Michele Del Vecchio, Piotr Rutkowski iD, Francesco Spagnolo iD, Jacek Mackiewicz, Vanna Chiarion-Sileni iD, John M Kirkwood iD, Caroline Robert iD, Jean-Jacques Grob iD und 8 weitere

Journal of Clinical Oncology · 10.05.2024 · 42 (14) · 1619-1624

DOI: 10.1200/jco.23.02355 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.05.2024. Verfasst von Jason J Luke und 19 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA. Hauptthemen laut MEDLINE: Melanoma, Antibodies, Monoclonal, Humanized, Neoplasm Staging, Skin Neoplasms. Die Arbeit wurde bisher 122-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Pembrolizumab adjuvant therapy was shown to significantly improve recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with resected stage IIB or IIC melanoma in earlier analyses of the randomized, double-blind, phase III KEYNOTE-716 study (ClinicalTrials.gov identifier: NCT03553836 ). We report results of the protocol-specified final analysis of DMFS for KEYNOTE-716. Overall, 976 patients were randomly allocated to pembrolizumab (n = 487) or placebo (n = 489). As of January 4, 2023, median follow-up was 39.4 months (range, 26.0-51.4 months). The median DMFS was not reached in either treatment group, and the estimated 36-month DMFS was 84.4% for pembrolizumab and 74.7% for placebo (hazard ratio [HR], 0.59 [95% CI, 0.44 to 0.79]). The median RFS was not reached in either treatment group, and the estimated 36-month RFS was 76.2% for pembrolizumab and 63.4% for placebo (HR, 0.62 [95% CI, 0.49 to 0.79]). DMFS and RFS results were consistent across most prespecified subgroups, including stage IIB and stage IIC melanoma. The safety profile of pembrolizumab was manageable and consistent with previous reports. These results continue to support the use of pembrolizumab adjuvant therapy in patients with resected stage IIB or IIC melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaAntibodies, Monoclonal, HumanizedNeoplasm StagingSkin NeoplasmsAntineoplastic Agents, ImmunologicalHumansFemaleMaleMiddle AgedChemotherapy, AdjuvantAgedDouble-Blind MethodAdultDisease-Free SurvivalAged, 80 and over

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • UPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA.
  • Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
  • Fiona Stanley Hospital and Edith Cowan University, Perth, WA, Australia.
  • Instituto de Biomedicina de Sevilla (IBiS)/Hospital Universitario Virgen Macarena/CSIC/Universidad de Sevilla, Seville, Spain.
  • Department of Clinical Oncology, Hospital University Virgen Macarena, Seville, Spain.
  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

ORCID-Profile: Jason J Luke, Paolo A Ascierto, Luis de la Cruz Merino, Piotr Rutkowski, Francesco Spagnolo, Vanna Chiarion-Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Dirk Schadendorf, Mizuho Fukunaga-Kalabis, Alexander M M Eggermont, Georgina V Long

Zitieren

APA

Luke, J. J., Ascierto, P. A., Khattak, M. A., de la Cruz Merino, L., Del Vecchio, M., Rutkowski, P., Spagnolo, F., Mackiewicz, J., Chiarion-Sileni, V., Kirkwood, J. M., Robert, C., Grob, J. J., de Galitiis, F., Schadendorf, D., Carlino, M. S., Wu, X. L., Fukunaga-Kalabis, M., Krepler, C., Eggermont, A. M. M., & Long, G. V. (2024). Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. Journal of Clinical Oncology, 42(14), 1619-1624. https://doi.org/10.1200/jco.23.02355

Vancouver

Luke JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, et al. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. Journal of Clinical Oncology. 2024;42(14):1619-1624. doi:10.1200/jco.23.02355

BibTeX
@article{Luke2024,
  author = {Luke, Jason J and Ascierto, Paolo A and Khattak, Muhammad A and de la Cruz Merino, Luis and Del Vecchio, Michele and Rutkowski, Piotr and Spagnolo, Francesco and Mackiewicz, Jacek and Chiarion-Sileni, Vanna and Kirkwood, John M and Robert, Caroline and Grob, Jean-Jacques and de Galitiis, Federica and Schadendorf, Dirk and Carlino, Matteo S and Wu, Xi Lawrence and Fukunaga-Kalabis, Mizuho and Krepler, Clemens and Eggermont, Alexander M M and Long, Georgina V},
  title = {Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {14},
  pages = {1619--1624},
  doi = {10.1200/jco.23.02355}
}
Kostenlos starten →